Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03493607Phase 2Completed

AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy

Role: lead

NCT04388774Phase 1Completed

Low-Dose Ketamine in Children With ADNP Syndrome

Role: lead

NCT02710084Phase 2Completed

Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome

Role: lead

NCT01183221Phase 2Completed

The Effects of Oxytocin on Complex Social Cognition in Autism Spectrum Disorders

Role: lead

All 4 trials loaded